Coronapod: the biomarker that could change COVID vaccines
Since the beginning oft he pandemic, researchers have searched for a biomarker which indicates immune protection from COVID-19 known as a correlate of protection. Now, the team developing the Oxford–AstraZeneca COVID-19 vaccine have published the first results of their so-called 'breakthrough study' which indicated puts forwards thresholds of neutralising antibodies that they suggest correlate with protection. The hope is that, should these results be confirmed, such biomarkers could speed up the development of new vaccines, and provide better ways to monitor the efficacy of tweaked vaccine aimed at fighting variants.
See acast.com/privacy for privacy and opt-out information.